5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
about
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidinesPretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).New advances in DPYD genotype and risk of severe toxicity under capecitabine.A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsLC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingPharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?A novel low-volume two-chamber microfabricated platform for evaluating drug metabolism and toxicity.Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityXELOX in colorectal cancer: a convenient option for the future?Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Therapeutic drug monitoring of 5-fluorouracil.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis.Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteersA well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutationOne pot synthesis, antimicrobial and antioxidant activities of fused uracils: pyrimidodiazepines, lumazines, triazolouracil and xanthines.Indirect assessment of dihydropyrimidine dehydrogenase activity in cats.A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.In vivo distribution of 5-Fluorouracil after peritumoral implantation using a biodegradable micro-device in tumor-bearing mice.
P2860
Q28534572-4F94A14F-3568-4999-AF25-3744268FB852Q33397773-6F77F92D-2ADC-4B46-88BF-5E4DE486B70EQ33418614-36343FF3-7ED9-4CDC-87B8-D9702683F855Q33648195-C6E535EF-49EA-4237-AD04-AEC486454F8AQ33810014-78D1B25A-A12B-43CC-AA92-C2540C6D440DQ33848566-50205FE2-7079-446E-B18A-E9BC1791AF65Q34008793-7AA0CDF1-2C3F-4FE0-914E-E4108F75BBE6Q34210342-FE57D24D-4313-45CA-8D41-9C01EC320649Q34216563-96C7B96B-F30A-4603-AA43-01A6727C9276Q34367423-72D05EFF-C57F-490E-9204-0F08839D342BQ34612932-9FFC1B61-19E6-4388-BFC6-82F95D7ADCF6Q34636318-DE1E1CA7-10E2-4CE1-A1A3-853631D7D280Q35109800-E6146625-8DE1-4D12-B59F-2A6678874D34Q35563540-A78B13EC-C753-4A45-8B6F-21BA122D11F7Q35584977-BCF6F748-5285-43DE-B3AE-092564A87D1FQ35743233-41B98E37-0012-4DA3-834E-043E65713DF6Q36117656-2BE4ABED-77FD-4C94-9C49-D45A943146FDQ36609043-A733FB0F-2822-467C-8DBE-3E80A03D943DQ37190389-84E7F6F3-2937-4CEA-B3BC-F1634F645544Q37290672-408C4FB8-B3FB-445F-B905-1B0ECA38A63DQ37839084-8B5DE087-3BC0-46F3-A01A-97229BCCB610Q38104743-73E8D492-C4DA-42A7-BB5B-51F4C7078F42Q38121743-28920AA4-D4F0-49DE-9399-98C25F167C4FQ38127715-35AA89BA-F233-4422-8A82-2EE6793544B4Q38565029-03095207-69C0-4D0B-B00C-376B3C2BC52EQ38842633-0573D4DA-EF32-4174-A626-D05E86FF9F29Q39208906-492D7F07-73DC-48A5-B9FA-BF3577817B6DQ39566084-84389252-D081-43E2-8A54-74D05C82F630Q40183302-78C41E7E-CBDE-4FF6-AD7B-A7BD3EED9911Q40234339-F25D3417-6DB8-4715-81F6-F1C7508A385CQ40805012-5F133B1D-0C78-48A4-91FF-9373E4C3CF4DQ42177462-DB72BE63-B4AC-433E-8FFD-AA94D0E9106AQ42318180-145C67AB-F3BD-4EBE-80E7-2840B19605F7Q42388782-E729786B-5E14-4853-9FE9-5D6CD7A59AAAQ42673945-8895FF88-A075-43EE-878B-F922A316161BQ42929441-752AC047-40F1-44DB-A085-6CDA0CC1630BQ45744185-2B6DACFB-10C1-44AE-ACBA-8BC73A33F54DQ45796639-8D6F4505-A389-4251-A140-440351CC318AQ45980539-2E23D10F-813B-4DFC-9C5F-7D9CF3F44165Q46036180-D5072A63-312E-48B3-81E6-B4B5CA86AC43
P2860
5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
5-Fluorouracil-related severe ...... dine dehydrogenase deficiency.
@en
type
label
5-Fluorouracil-related severe ...... dine dehydrogenase deficiency.
@en
prefLabel
5-Fluorouracil-related severe ...... dine dehydrogenase deficiency.
@en
P2093
P1433
P1476
5-Fluorouracil-related severe ...... dine dehydrogenase deficiency.
@en
P2093
Boisdron-Celle M
Poirier AL
P304
P356
10.1016/J.CANLET.2006.09.006
P407
P577
2006-10-24T00:00:00Z